United States Patent 8,367,605 (Copolymer-1): Claim Scope, Patent Landscape, and Freedom-to-Operate Risks

Executive summary: U.S. Patent 8,367,605 claims a specific Copolymer-1 composition for multiple sclerosis built from alanine, glutamic acid, lysine, and tyrosine residues in a defined molar ratio (about 6:2:5:1), with a controlled high–molecular-weight tail (less than 5% above 40 kDa in claim 1; less than 2.5% above 40 kDa in dependent claims). The claims also narrow the synthetic route to polymerization of suitably protected amino acid carboxyanhydrides, with a further dependent embodiment specifying particular N-carboxyanhydrides (alanine, tyrosine, 7-benzyl glutamate, and ε-N-trifluoroacetyllysine). This creates a landscape where (i) “Copolymer-1 for MS” is crowded, but (ii) the most relevant infringement and design-around questions turn on distribution of molecular weight above 40 kDa, residue ratio, and whether manufacturing uses the same carboxyanhydride chemistry and protecting groups.

What patents protect Copolymer-1 compositions for treating multiple sclerosis in the US?

Core answer: The patent protection most directly anchored around the specific “Copolymer-1” building blocks and formulation attributes is typically split across: (1) composition claims defining amino acid ratios and molecular weight distribution, (2) method claims for treating multiple sclerosis, and (3) process claims tied to polymerization of protected amino acid N-carboxyanhydrides. U.S. 8,367,605 is positioned in the first two buckets, with process-linked specificity in dependent claim 3.

Patent estate structure around Copolymer-1

At a high level, Copolymer-1 patent estates in the US tend to cluster into three claim families:

Composition scope families
- Defined copolymer residues and molar ratios (alanine/glutamic acid/lysine/tyrosine).
- Defined molecular weight distribution limits (often controlling high MW fraction).
- Defined sequence and non-uniformity features (sequence microheterogeneity).
Method-of-use families
- Claims to treating relapsing or chronic progressive multiple sclerosis with the composition.
- These claims often function as “use overlays” that extend protection even when the composition is similar.
Manufacturing/process families
- Polymerization of suitably protected amino acid carboxyanhydrides (N-carboxyanhydrides).
- Particular protecting groups for glutamate and lysine residues can be used to distinguish process variants.
- These claims can create barriers to generic-style re-manufacturing even when composition targets are met.

Where U.S. 8,367,605 fits

U.S. 8,367,605 is a composition-centric patent with treatment suitability. The claim language puts infringement emphasis on:

Residue molar ratio: approximately 6:2:5:1 (alanine:glutamic acid:lysine:tyrosine).
Copolymer heterogeneity: “non-uniform with respect to molecular weight and sequence.”
High-MW cutoff: less than 5% of copolymers have MW above 40 kDa (claim 1) or less than 2.5% (claim 2/4).
Manufacturing chemistry:
- Claim 1: polymerization of “suitably protected amino acid carboxyanhydrides.”
- Claim 3: polymerization of N-carboxyanhydrides of alanine, tyrosine, 7-benzyl glutamate, and ε-N-trifluoroacetyllysine.

What is the exact scope of claim 1 of US 8,367,605 (molar ratio, molecular weight tail, sequence heterogeneity)?

Featured-snippet answer: Claim 1 covers a Copolymer-1 mixture with alanine/glutamic acid/lysine/tyrosine at ~6:2:5:1, containing a non-uniform distribution of molecular weight and sequence, where fewer than 5% of the copolymer species exceed 40 kDa, and made by polymerizing suitably protected amino acid carboxyanhydrides, and suitable for treating multiple sclerosis.

Claim 1 elements mapped to infringement “touchpoints”

For a US infringement analysis, claim 1 breaks into distinct, independently provable limitations:

Composition identity
- “A copolymer-1 composition comprising a mixture of copolymers”
- Residue set is limited to alanine, glutamic acid, lysine and tyrosine.
Molar ratio
- “in a molar ratio of approximately 6:2:5:1”
- The word “approximately” creates room for minor analytical variance but still constrains to the neighborhood of the stated ratio.
Sequence and MW distribution heterogeneity
- “the copolymer species in the mixture being non-uniform with respect to molecular weight and sequence”
- This signals that the claimed product is not a single uniform polymer species.
High molecular weight tail limit
- “less than 5% of the copolymers have a molecular weight above 40 kDa”
- This is a quantitative cutoff that likely drives both testing methods and design-around strategies.
Synthetic route requirement
- “synthesized by polymerization of suitably protected amino acid carboxyanhydrides”
- This ties infringement not only to end composition but also to how it is made.
Indication suitability
- “suitable for treating multiple sclerosis”
- This element can be litigated as product suitability or use claims depending on the patent’s structure, but the claim is drafted as a composition “suitable for” an MS treatment.

Practical scope implications

If a competitor makes Copolymer-1 with the correct residue ratio but produces a molecular weight distribution with a high-MW fraction above 5%, it falls outside claim 1 even if still “Copolymer-1-like.”
If the residue ratio and MW tail are within limits but the process uses a non-carboxyanhydride route (or different protecting group class without “suitably protected” correspondence), it may avoid claim 1 depending on how broadly “suitably protected” is construed.

How does dependent claim 2 narrow US 8,367,605 (high-MW cutoff 2.5% vs 5%)?

Featured-snippet answer: Claim 2 narrows claim 1 by requiring fewer than 2.5% of copolymer species above 40 kDa.

Claim 2 key delta

Claim 1: <5% above 40 kDa
Claim 2: <2.5% above 40 kDa

Infringement and design-around leverage

Molecular weight distribution is a controllable manufacturing parameter (polymerization time, purification, fractionation, quench conditions).
A design-around strategy frequently attempted in polymer therapeutics is to target a tighter MW distribution by controlling reaction kinetics or by post-processing fractions.
Claim 2 effectively creates a second tier protection level. If a product is engineered to be <2.5%, it sits within both claim 2 and claim 1; if it is between 2.5% and 5%, it may still infringe claim 1 but avoid claim 2.

What is the added manufacturing limitation in claim 3 of US 8,367,605 (specific N-carboxyanhydrides)?

Featured-snippet answer: Claim 3 limits the synthesis to polymerization of N-carboxyanhydrides of alanine, tyrosine, 7-benzyl glutamate, and ε-N-trifluoroacetyllysine.

Claim 3 adds two layers of specificity

Synthesis specificity beyond “suitably protected”
- Claim 1 is generic: “suitably protected amino acid carboxyanhydrides.”
- Claim 3 is specific: named N-carboxyanhydrides with named protecting groups.
Protecting group identity anchors
- 7-benzyl glutamate indicates glutamate is protected via benzyl on the side chain (commonly used to direct/enable polymerization chemistry).
- ε-N-trifluoroacetyllysine indicates lysine side-chain amine is protected by a trifluoroacetyl group.

How this impacts claim scope

Products made via alternative protecting groups or alternative carboxyanhydrides (for example, different glutamate protecting group chemistry or lysine protecting groups) may not meet claim 3 even if they meet claim 1.
Claim 3 is narrower than claim 1 and typically offers less value to a generic-like entrant if they can alter protecting-group chemistry while maintaining overall residue ratio and molecular weight tail.

How does dependent claim 4 combine the tighter MW cutoff with the specific lysine/glutamate carboxyanhydrides?

Featured-snippet answer: Claim 4 requires both: (i) the claim 3 synthesis using alanine/tyrosine/7-benzyl glutamate/ε-N-trifluoroacetyllysine N-carboxyanhydrides, and (ii) fewer than 2.5% of copolymer species above 40 kDa.

Scope hierarchy

Claim 1: composition + general protected carboxyanhydride synthesis + <5% above 40 kDa.
Claim 2: all claim 1 elements + <2.5% above 40 kDa.
Claim 3: all claim 1 elements + specific N-carboxyanhydrides.
Claim 4: claim 3 + <2.5% above 40 kDa.

Litigation relevance

Claim 4 creates a highly specific “best-in-class” product/process embodiment. Even if a competitor avoids claim 3 by using different protecting groups, claim 1 may still be asserted if the competitor’s process meets “suitably protected” and product distribution is inside the <5% tail.
Conversely, if a competitor avoids claim 1 by moving MW tail above 5%, it may avoid both claim 2 and claim 4 even if using the exact N-carboxyanhydrides.

What objective tests map to the claim limitations (residue ratio and “% above 40 kDa”)?

Featured-snippet answer: The two most evidentiary claim elements are (1) the amino acid residue molar ratio near 6:2:5:1 and (2) the fraction of copolymer species above 40 kDa, which requires distribution measurement that can be reported as a percent exceeding a molecular weight threshold.

Molecular weight distribution measurement risks

Claim 1 and 2 use a quantitative threshold: “less than X% of the copolymers have a molecular weight above 40 kDa.” That phrase typically requires:

Separation or analytical methods that can estimate molecular weight distribution of the copolymer species in the mixture.
Reporting convention clarity: whether percent is number-based, weight-based, or species-fraction-based.
Reproducibility across batches.

Residue ratio measurement risks

The “molar ratio of approximately 6:2:5:1” is analytically anchored to composition after hydrolysis or segment determination methods. Variability can occur with:

Partial degradation of side chains during analysis.
Incomplete recovery of certain residues.
Analytical method-to-method comparability.

“Non-uniform with respect to molecular weight and sequence”

This element adds a qualitative requirement. In dispute, it can become an evidentiary proxy for:

Heterogeneity in sequence distribution.
Evidence that the product is a mixture with microheterogeneity rather than a uniform polymer.

Which generic entry risks exist for Copolymer-1 based on this claim set?

Featured-snippet answer: The primary generic entry risk under U.S. 8,367,605 is failing the molecular weight tail requirement (<5% or <2.5% above 40 kDa) while matching the residue ratio. A secondary risk is infringing manufacturing-route limitations if the competitor uses polymerization of suitably protected carboxyanhydrides and, for claim 3/4, the same specific carboxyanhydrides.

Generic-style manufacturing scenario matrix

Competitor strategy	Likely claim coverage under 8,367,605
Match residue ratio and MW tail <5%, use carboxyanhydride polymerization with protected AAs	High risk for claim 1
Keep residue ratio but produce MW tail 5–10% above 40 kDa	Reduced risk for claim 1; may avoid 2/4 as well
Use carboxyanhydride chemistry but with different protecting groups vs 7-benzyl glutamate and ε-N-trifluoroacetyllysine	Potentially avoid claim 3/4 while remaining exposed to claim 1 if “suitably protected” is met
Fractionate or purify to tighten MW distribution <2.5%	Infringement risk increases for claim 2/4 if other elements align
Change process to non-carboxyanhydride route but match product composition	Potentially reduces claim 1 risk if route limitations are strictly construed

How strong is the patent estate for US 8,367,605 (what is inherently narrow vs broadly reusable)?

Featured-snippet answer: The patent is narrow on the quantitative MW distribution and the specific amino acid ratio, but it is broadly written on “suitably protected amino acid carboxyanhydrides” in claim 1. That combination can yield a strong enforcement position against products with similar distributions while leaving multiple manufacturing design-around options via high-MW fraction control and protecting-group substitutions.

Strength factors tied to claim drafting

Quantitative limiter (<5% and <2.5% above 40 kDa): strong for enforcement because it can be tested and is often hard to hit precisely across scale-up.
Residue ratio “approximately 6:2:5:1”: anchors identity but leaves some tolerance.
Process linkage in claim 1: importing manufacturing steps can broaden coverage if construed broadly, but it can also narrow infringement if construed narrowly.

Weakness / narrowing opportunities

Competitors can attempt to:
- Increase high-MW fraction beyond the cutoff while keeping therapeutic performance.
- Use different protecting groups and different specific N-carboxyanhydrides to avoid claim 3/4.
The “non-uniform sequence” limitation can be litigated; if a competitor’s product is argued to be “uniform” by their characterization method, claim 1 could be contested.

What patent litigation effects and settlement dynamics typically matter for this kind of claim?

Featured-snippet answer: For a composition claim that includes both a quantitative MW distribution cutoff and a route limitation (carboxyanhydride polymerization), litigation leverage typically concentrates on analytical comparability and process-to-product translation: whether the accused product meets the <40 kDa fraction metric and whether its manufacturing uses polymerization of the claimed protected carboxyanhydrides.

Litigation battlegrounds likely to recur

Expert battle on molecular weight fraction:
- Method selection and threshold calculation.
- Whether “copolymers have a molecular weight above 40 kDa” corresponds to a defined analytical “species” definition.
Residue ratio and tolerances
Process evidence
- Batch records and supplier documentation for carboxyanhydride starting materials.
- Whether “suitably protected” includes alternative protecting group chemistries.

How does US 8,367,605 compare with broader “Copolymer-1 for MS” protection?

Featured-snippet answer: U.S. 8,367,605 is more specific than broad “Copolymer-1” patents because it adds explicit MW distribution cutoffs and, in dependent claims, explicit N-carboxyanhydride identities. Broader patents often cover the concept of Copolymer-1 for MS regardless of MW tail distribution; U.S. 8,367,605 narrows to products with controlled molecular weight profiles.

Practical comparison framework

If another patent claims Copolymer-1 with only general amino acid composition but no MW cutoff, U.S. 8,367,605 becomes a stronger tool against products matching composition but not distribution.
If another patent claims method-of-use without composition MW limits, U.S. 8,367,605 will not fully substitute; it may still leave method claims available.

What is the Orange Book status of US 8,367,605 and how does it affect entry timing?

No response provided because US Orange Book status requires the specific FDA product listing and Orange Book patent-to-code mapping, which is not contained in the prompt.

Key takeaways

Claim 1 defines a Copolymer-1 composition by identity (alanine/glutamic acid/lysine/tyrosine), target molar ratio (~6:2:5:1), heterogeneity (non-uniform molecular weight and sequence), a quantitative high-MW tail limit (<5% above 40 kDa), and a manufacturing route (polymerization of suitably protected amino acid carboxyanhydrides).
Dependent claim 2 tightens the MW tail cutoff to <2.5% above 40 kDa.
Dependent claims 3 and 4 add specific synthetic starting points: alanine and tyrosine N-carboxyanhydrides, 7-benzyl glutamate N-carboxyanhydride, and ε-N-trifluoroacetyllysine N-carboxyanhydride; claim 4 also requires the tighter <2.5% cutoff.
Freedom-to-operate risk for a competitor concentrates on meeting or missing the <40 kDa high-MW fraction and on whether the manufacturing process aligns with carboxyanhydride polymerization and, for claim 3/4, the specific protecting groups.

FAQs

How do courts typically interpret “approximately 6:2:5:1” in composition residue ratios?
What analytical standards best support proving “less than X% above 40 kDa” in polymer mixtures?
Can a process using carboxyanhydride polymerization with different protecting groups avoid claim 3 while still infringing claim 1?
If a product meets MW and residue ratio limits but is “made” via a different route than carboxyanhydride polymerization, does claim 1 still apply?
How does “non-uniform with respect to molecular weight and sequence” get established experimentally in infringement disputes?

References

No citations provided because the prompt includes only claim text and does not include source documents (e.g., USPTO publication, specification, prosecution history, or FDA Orange Book listing) needed to support numbered APA references.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0762888	⤷ Start Trial	90987	Luxembourg	⤷ Start Trial
European Patent Office	0762888	⤷ Start Trial	C300096	Netherlands	⤷ Start Trial
European Patent Office	0762888	⤷ Start Trial	C300251	Netherlands	⤷ Start Trial
Austria	212857	⤷ Start Trial
Australia	1016102	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,367,605

Summary for Patent: 8,367,605